M. Clark, J. Colombel, B. Feagan, R. Fedorak, S. Hanauer et al., American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21???23, 2006, Gastroenterology, vol.133, issue.1, pp.312-351, 2006.
DOI : 10.1053/j.gastro.2007.05.006

D. Knight, H. Trinh, J. Le, S. Siegel, D. Shealy et al., Construction and initial characterization of a mouse-human chimeric anti-TNF antibody, Molecular Immunology, vol.30, issue.16, pp.1443-53, 1993.
DOI : 10.1016/0161-5890(93)90106-L

H. Fidder, F. Schnitzler, M. Ferrante, M. Noman, K. Katsanos et al., Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study, Gut, vol.58, issue.4, pp.501-509, 2009.
DOI : 10.1136/gut.2008.163642

J. Kelsall, P. Rogers, G. Galindo, D. Vera, and M. , Safety of Infliximab Treatment in Patients with Rheumatoid Arthritis in a Real-world Clinical Setting: Description and Evaluation of Infusion Reactions, The Journal of Rheumatology, vol.39, issue.8, pp.1539-1584, 2012.
DOI : 10.3899/jrheum.110956

F. Aeschlimann, K. Hofer, C. Schneider, E. Schroeder, S. Lauener et al., Infliximab in Pediatric Rheumatology Patients: A Retrospective Analysis of Infusion Reactions and Severe Adverse Events During 2246 Infusions over 12 Years, The Journal of Rheumatology, vol.41, issue.7, pp.1409-1424, 2014.
DOI : 10.3899/jrheum.131231

W. Miehsler, G. Novacek, H. Wenzl, H. Vogelsang, P. Knoflach et al., A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease, Journal of Crohn's and Colitis, vol.31, issue.suppl 1, pp.221-56, 2010.
DOI : 10.2165/0002018-200831120-00009

A. Cheifetz, M. Smedley, S. Martin, M. Reiter, G. Leone et al., The incidence and management of infusion reactions to infliximab: a large center experience, The American Journal of Gastroenterology, vol.134, issue.6, pp.1315-1339, 2003.
DOI : 10.1016/S0140-6736(02)08512-4

H. Hamzaoglu, J. Cooper, M. Alsahli, K. Falchuk, M. Peppercorn et al., Safety of infliximab in Crohn??s disease, Inflammatory Bowel Diseases, vol.126, issue.12, pp.2109-2125, 2010.
DOI : 10.1053/j.gastro.2004.02.070

W. Pichler, Adverse side-effects to biological agents, Allergy, vol.4, issue.4, pp.912-932, 2006.
DOI : 10.4161/cbt.4.8.1893

P. Campi, M. Benucci, M. Manfredi, and P. Demoly, Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-?? antagonists, Current Opinion in Allergy and Clinical Immunology, vol.7, issue.5, p.393, 2007.
DOI : 10.1097/ACI.0b013e3282ef96df

C. Chung, B. Mirakhur, E. Chan, Q. Le, J. Berlin et al., Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-??-1,3-Galactose, New England Journal of Medicine, vol.358, issue.11, pp.1109-1126, 2008.
DOI : 10.1056/NEJMoa074943

A. Vultaggio, A. Matucci, F. Nencini, S. Pratesi, G. Petroni et al., Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab, International Archives of Allergy and Immunology, vol.29, issue.3, pp.321-327, 2012.
DOI : 10.1016/j.vaccine.2010.12.072

A. Vultaggio, A. Matucci, F. Nencini, S. Pratesi, P. Parronchi et al., Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions, Allergy, vol.21, issue.5, pp.657-61, 2010.
DOI : 10.1097/ACI.0b013e3282ef96df

S. Candon, A. Mosca, F. Ruemmele, O. Goulet, L. Chatenoud et al., Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease, Clinical Immunology, vol.118, issue.1, pp.11-20, 2006.
DOI : 10.1016/j.clim.2005.07.010

S. Kato, T. Kobayashi, K. Kani, H. Takabayashi, R. Yamamoto et al., Elevated serum IgE prior to acute severe infusion reaction during infliximab maintenance therapy in a crohn??s disease patient, Inflammatory Bowel Diseases, vol.7, issue.12, pp.156-163, 2011.
DOI : 10.1046/j.1526-0968.2003.00012.x

A. Vultaggio, A. Matucci, F. Nencini, S. Pratesi, and M. E. , Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction, Internal and Emergency Medicine, vol.20, issue.S2, pp.77-86, 2012.
DOI : 10.1016/j.coi.2008.06.011

A. Matucci, S. Pratesi, G. Petroni, F. Nencini, G. Virgili et al., Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab, Clin Exp Allergy J Br Soc Allergy Clin Immunol, vol.43, pp.659-64, 2013.

A. Babouri, A. Buisson, M. Bigard, and L. Peyrin-biroulet, Tolerability of one hour 10mg/kg infliximab infusions in patients with inflammatory bowel disease, Journal of Crohn's and Colitis, vol.354, issue.2, pp.129-162, 2013.
DOI : 10.1016/S0140-6736(99)05246-0

A. Babouri, X. Roblin, J. Filippi, X. Hébuterne, M. Bigard et al., Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: A prospective multicenter cohort study, Journal of Crohn's and Colitis, vol.38, issue.2, pp.161-166, 2014.
DOI : 10.1111/apt.12389

URL : https://hal.archives-ouvertes.fr/hal-01699626

A. Barbaud, F. Granel, J. Waton, and C. Poreaux, How to manage hypersensitivity reactions to biological agents?, Eur J Dermatol, vol.21, p.667, 2011.

A. Olszewski, L. Pons, F. Moutété, I. Aimone-gastin, G. Kanny et al., Isolation and characterization of proteic allergens in refined peanut oil, Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy, vol.225, issue.7, pp.850-859, 1998.
DOI : 10.1111/j.1432-1033.1994.00609.x

K. Brockow, A. Romano, M. Blanca, J. Ring, W. Pichler et al., General considerations for skin test procedures in the diagnosis of drug hypersensitivity, Allergy, vol.57, pp.45-51, 2002.

A. Barbaud, M. Gonçalo, D. Bruynzeel, and A. Bircher, Guidelines for performing skin tests withdrugs in the investigation of cutaneous adverse drug reactions . Proposed by the Working party of the ESCD for the study of skin testing in investigating cutaneous adverse drug reactions, Contact Dermatitis, vol.29, issue.6, pp.321-329, 2001.
DOI : 10.1034/j.1600-0536.2001.450502.x

D. Hong, L. Bankova, K. Cahill, T. Kyin, and M. Castells, Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies, Expert Review of Clinical Immunology, vol.110, issue.1, pp.43-54, 2012.
DOI : 10.1067/mai.2002.128689

S. Vermeire, G. Van-assche, and P. Rutgeerts, Serum sickness, encephalitis and other complications of anti-cytokine therapy, Best Practice & Research Clinical Gastroenterology, vol.23, issue.1, pp.101-113, 2009.
DOI : 10.1016/j.bpg.2008.12.005

O. Meara, S. Nanda, K. Moss, and A. , O-003???Relationship Between Vedolizumab Pharmacokinetics and Endoscopic Outcomes of Patients With Ulcerative Colitis, Inflammatory Bowel Diseases, vol.20, pp.1-6, 2014.
DOI : 10.1097/01.MIB.0000456699.04243.9e

K. Nanda, A. Cheifetz, and A. Moss, Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis, The American Journal of Gastroenterology, vol.60, issue.1, pp.40-47, 2013.
DOI : 10.1016/j.clim.2005.07.010

F. Baert, M. Noman, S. Vermeire, G. Van-assche, D. Haens et al., Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease, New England Journal of Medicine, vol.348, issue.7, pp.601-609, 2003.
DOI : 10.1056/NEJMoa020888

S. Hanauer, B. Feagan, G. Lichtenstein, L. Mayer, S. Schreiber et al., Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, The Lancet, vol.359, issue.9317, pp.1541-1550, 2002.
DOI : 10.1016/S0140-6736(02)08512-4

P. Marits, L. Landucci, U. Sundin, L. Davidsdottir, J. Nilsson et al., Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment, Journal of Crohn's and Colitis, vol.11, issue.4, pp.881-890, 2014.
DOI : 10.1016/j.cgh.2012.10.020

P. Brennan, T. Bouza, F. Hsu, D. Sloane, and M. Castells, Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment, Journal of Allergy and Clinical Immunology, vol.124, issue.6, pp.1259-66, 2009.
DOI : 10.1016/j.jaci.2009.09.009

J. Lelong, C. Duburque, C. Fournier, J. Colombel, P. Desreumaux et al., Accoutumance m??dicamenteuse ?? l???infliximab dans la maladie de Crohn, Revue des Maladies Respiratoires, vol.22, issue.2, p.239, 2005.
DOI : 10.1016/S0761-8425(05)85477-4

K. Brockow, L. Garvey, W. Aberer, M. Atanaskovic-markovic, A. Barbaud et al., Skin test concentrations for systemically administered drugs - an ENDA/EAACI Drug Allergy Interest Group position paper, Allergy, vol.17, issue.6, pp.702-714, 2013.
DOI : 10.1111/j.1398-9995.2009.02088.x

S. Hwang, H. Yoo, M. Yoon, and H. Park, Detection of IgE binding component to infliximab in a patient with infliximab-induced anaphylaxis, Annals of Allergy, Asthma & Immunology, vol.112, issue.4, pp.393-397, 2014.
DOI : 10.1016/j.anai.2014.02.001

S. Ben-horin, Y. Mazor, H. Yanai, R. Y. Kopylov, U. Yavzori et al., The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD, Alimentary Pharmacology & Therapeutics, vol.105, issue.6, pp.714-736, 2012.
DOI : 10.1002/ibd.21919

J. Wee, G. Petrof, K. Jackson, J. Barker, and C. Smith, Infliximab for the treatment of psoriasis in the U.K.: 9???years??? experience of infusion reactions at a single centre, British Journal of Dermatology, vol.16, issue.2, pp.411-417, 2012.
DOI : 10.1002/ibd.21279

J. Colombel, W. Sandborn, W. Reinisch, G. Mantzaris, A. Kornbluth et al., Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease, New England Journal of Medicine, vol.362, issue.15, pp.1383-95, 2010.
DOI : 10.1056/NEJMoa0904492

S. Vermeire, M. Noman, G. Van-assche, F. Baert, D. Haens et al., Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease, Gut, vol.56, issue.9, pp.1226-1257, 2007.
DOI : 10.1136/gut.2006.099978

C. Steenholdt, M. Svenson, K. Bendtzen, O. Thomsen, J. Brynskov et al., Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, vol.31, issue.1, pp.51-59, 2011.
DOI : 10.1111/j.1365-2036.2009.04206.x

C. Steenholdt, Y. Palarasah, K. Bendtzen, A. Teisner, J. Brynskov et al., Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, vol.2, issue.12, pp.1172-83, 2013.
DOI : 10.1016/S1542-3565(04)00238-1

I. Uthman, Z. Touma, J. El-sayyad, and F. Zaitoun, Successful retreatment with infliximab in patients with prior severe infusion reactions, Clinical Rheumatology, vol.97, issue.6, pp.540-541, 2006.
DOI : 10.1016/S0196-0644(00)43749-2

A. Youdim, E. Vasiliauskas, S. Targan, K. Papadakis, A. Ippoliti et al., A Pilot Study of Adalimumab in Infliximab-Allergic Patients, Inflammatory Bowel Diseases, vol.95, issue.4, pp.333-341, 2004.
DOI : 10.1016/0016-5085(95)90277-5

W. Sandborn, S. Hanauer, E. Loftus, W. Tremaine, S. Kane et al., An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease, The American Journal of Gastroenterology, vol.52, issue.10, pp.1984-1993, 2004.
DOI : 10.1053/gast.2003.50182

H. Ang and S. Helfgott, Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factoralpha antagonists in patients with rheumatoid arthritis?, J Rheumatol, vol.30, pp.2315-2323, 2003.

A. Stallmach, T. Giese, C. Schmidt, S. Meuer, and S. Zeuzem, Severe anaphylactic reaction to infliximab, European Journal of Gastroenterology & Hepatology, vol.16, issue.6, pp.627-657, 2004.
DOI : 10.1097/00042737-200406000-00018

C. Steenholdt, M. Svenson, K. Bendtzen, O. Thomsen, J. Brynskov et al., Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease, Journal of Crohn's and Colitis, vol.2, issue.1, pp.108-119, 2012.
DOI : 10.1016/S1542-3565(04)00238-1

F. Baert, D. Drobne, A. Gils, V. Casteele, N. Hauenstein et al., Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy, Clinical Gastroenterology and Hepatology, vol.12, issue.9, pp.1542-356500141, 2014.
DOI : 10.1016/j.cgh.2014.01.033

R. Farrell, M. Alsahli, Y. Jeen, K. Falchuk, M. Peppercorn et al., Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial, Gastroenterology, vol.124, issue.4, pp.917-941, 2003.
DOI : 10.1053/gast.2003.50145

J. Sany, M. Kaiser, C. Jorgensen, and G. Trape, Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.64, issue.11, pp.1647-1656, 2005.
DOI : 10.1136/ard.2005.037499

M. Wasserman, D. Weber, J. Guthrie, V. Bykerk, P. Lee et al., Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number, J Rheumatol, vol.31, pp.1912-1919, 2004.

P. Lahdenne, A. Wikström, K. Aalto, and K. Kolho, Prevention of acute adverse events related to infliximab infusions in pediatric patients, Arthritis Care & Research, vol.34, issue.6, pp.785-90, 2010.
DOI : 10.1136/ard.2007.070771

C. Duburque, J. Lelong, R. Iacob, M. Seddik, P. Desreumaux et al., Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions, Alimentary Pharmacology and Therapeutics, vol.1350, issue.5, pp.851-859, 2006.
DOI : 10.1001/jama.278.22.1895